EU Pharma Regulatory Law

2012 is set to be a critical year for EU pharma regulation with the implementation of the pharmacovigilance rules, proposals to amend the data protection and clinical trials directives and the new falsified medicinal products directive.

In addition, the Mediator case triggered an overhaul of regulation governing the healthcare sector in France and a drive towards increased transparency and the impact of this case is likely to be felt across the EU.

Questions are being raised about anti-corruption efforts and where we are a year on from the introduction of the UK Bribery Act.

There are a number of competition law developments, there are concerns regarding off-label promotion and a number of legal problems are arising as a result of pharma companies developing their social media presence.

The budgetary pressures across Europe and the Eurocrisis are having a critical impact on health authorities across Europe and the scope of SPCs has been clarified.

Don’t miss this outstanding opportunity to learn from and network with those at the forefront of pharma regulatory law in the EU Market. Confirm your participation today and be rewarded with a significant discount.

TO REQUEST A BROCHURE BE SENT AS SOON AS IT IS PRODUCED, PLEASE SEND AN EMAIL TO TOBY HARTLEY (T.HARTLEY@C5-ONLINE.COM) QUOTING 'PRLABR' IN THE SUBJECT LINE.

- Actions -

- Share -